**9. References**


Apoptosis Imaging in Diseased Myocardium 263

Kerr JF., Wyllie AH. & Currie AR. (1972). Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. *Br J Cancer* Vol.26(No. 4):239 –257 Kietselaer BL, Reutelingsperger CP, Boersma HH, Heidendal GA, Liem IH, Crijns HJ,

Narula J & Hofstra L. (2007) Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. *J Nucl Med* Vol.48(No. 4):562-567. Kown MH, Strauss HW, Blankenberg FG, Berry GJ, Stafford-Cecil S, Tait JF, Goris ML &

Robbins RC. (2001). In vivo imaging of acute cardiac rejection in human patients using (99m)technetium labeled annexin V. *Am J Transplant* Vol.1(No. 3):270-277. Murakami Y, Takamatsu H, Taki J, Tatsumi M, Noda A, Ichise R, Tait JF, Nishimura S.

(2004). 18F-labelled annexin V: a PET tracer for apoptosis imaging. *Eur J Nucl Med* 

Tomaszewski JE, Kelly C, Steinmetz N, Green A, Tait JF, Leppo J, Blankenberg FG, Jain D & Strauss HW. (2001). Annexin-V imaging for noninvasive detection of

phosphatidyl serine (PS) reversal in acute ischemic syndromes. *J Nucl Med* 

Beltrami CA, Krajewski S, Reed JC & Anversa P. (1997). Apoptosis in the failing

Meulemans A, Saumon G, Michel JB & Le Guludec D. (2004). Imaging apoptosis with (99m)Tc-annexin-V in experimental subacute myocarditis. *J Nucl Med*

G, Antoni G & Ziv I. (2008). Molecular imaging of neurovascular cell death in

& Voipio-Pulkki LM. (1999). Cardiomyocyte apoptosis and progression of heart

Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi.

characterization of annexin V mutants with endogenous chelation sites for (99m)Tc.

Tonami N & Strauss, HW. (2004). Detection of cardiomyocyte death in a rat model of ischemia and reperfusion using 99mTc-labeled annexin V. *J Nucl Med* Vol.45(No.

Vanderheyden JL & Strauss HW. (2007a). 99mTc-Annexin-V uptake in a rat model of variable ischemic severity and reperfusion time. *Circ J*. Vol.71(No. 7):1141-1146.

Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, Fitzpatrick JM, Raghunath PN,

Narula J & Strauss HW. (2003). Invited commentary: P.S.\* I love you: implications of

Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C,

Peker C, Sarda-Mantel L, Loiseau P, Rouzet F, Nazneen L, Martet G, Vrigneaud JM,

Reshef A, Shirvan A, Waterhouse RN, Grimberg H, Levin G, Cohen A, Ulysse LG, Friedman

experimental cerebral stroke by PET. *J Nucl Med* Vol.49(No. 9):1520-1528. Saraste A, Pulkki K, Kallajoki M, Heikkila P, Laine P, Mattila S, Nieminen MS, Parvinen M

Stratton JR, Dewhurst TA, Kasina S, Reno JM, Cerqueira MD, Baskin DG, et al. (1995).

Tait JF, Brown DS, Gibson DF, Blankenberg FG & Strauss HW. (2000). Development and

Tait JF, Smith C & Blankenberg FG. (2005). Structural requirements for in vivo detection of

Taki J, Higuchi T, Kawashima A, Tait JF, Kinuya S, Muramori A, Matsunari I, Nakajima K,

Taki J, Higuchi T, Kawashima A, Tait JF, Muramori A, Matsunari I, Nakajima, K,

cell death with 99mTc-annexin V. *J Nucl Med* Vol.46(No. 5):807-815.

failure to transplantation. *Eur J Clin Invest* Vol.29(No. 5):380-386.

cardiac allograft rejection. *Nat Med* Vol.7(No. 12):1347-1352.

human heart. N *Engl J Med* Vol.336(No. 16):1131-1141.

*Mol Imaging* Vol.31(No. 4):469-474.

Vol.44(No. 3):397-399.

Vol.45(No. 6):1081-1086.

9):1536-1541.

*Circulation*. Vol.92(No.10):3113-3121.

*Bioconjug Chem*. Vol.11(No. 6):918-925.

left ventricular function, and attenuates remodeling in rats with myocardial infarction. *J Am Coll Cardiol* Vol. 43(No.2): 295-301.


Dumont EA, Hofstra L, van Heerde WL, van den Eijnde S, Doevendans PA, DeMuinck E,

Dumont EA, Reutelingsperger CP, Smits JF, Daemen MJ, Doevendans PA, Wellens HJ &

photon emission computed tomography. *Mol Imaging* Vol.7(No. 3):132-138. Gavrieli Y, Sherman Y & Ben-Sasson S. (1992). Identification of programmed cell death in

Grierson JR, Yagle KJ, Eary JF, Tait JF, Gibson DF, Lewellen B, Link JM, & Krohn KA. (2004).

Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA, Kajstura J & Anversa P.

Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, De

Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G

contributing variables of infarct size in rats. *Lab Invest* Vol.74(No. 1):86-107. Kemerink GJ, Boersma HH, Thimister PW, Hofstra L, Liem IH, Pakbiers MT, Janssen D,

Kemerink GJ, Liu X, Kieffer D, Ceyssens S, Mortelmans L, Verbruggen AM, Steinmetz, ND,

Kenis H, Zandbergen HR, Hofstra L, Petrov AD, Dumont EA, Blankenberg FD, Haider, N,

infarction. *J Am Coll Cardiol* Vol. 43(No.2): 295-301.

Vol.102(No. 13):1564-1568.

3):493-501

Vol.15(No.2):373-379.

Vol.85(No.9):856-866.

*Lance*. Vol.356(No. 9225):209-212.

*Med* Vol.51(No. 2):259-267.

annexin V. *J Nucl Med* Vol.42(No. 2):382-387.

human application. *J Nucl Med* Vol.44(No. 6): 947-952.

left ventricular function, and attenuates remodeling in rats with myocardial

Daemen MA, Smits JF, Frederik P, Wellens HJ, Daemen MJ & Reutelingsperger CP. (2000). Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. *Circulation*

Hofstra L. (2001). Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. *Nat Med* Vol.7(No.12):1352-1355. Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Pin S, Tsao A, Wang Y, Sooryakumar D,

Yu SJ, Pomper MG & Tsui BM. (2008). Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-

situ via specific labeling of nuclear DNA fragmentation. *J Cell Biol* Vol.119(No.

Production of [F-18]fluoroannexin for imaging apoptosis with PET. *Bioconjug Chem*.

(1999) Myocyte death in the failing human heart is gender dependent. *Circ Res*

Muinck E, Wellens HJ, Kemerink GJ, Reutelingsperger CP & Heidendal GA. (2000). Visualisation of cell death in vivo in patients with acute myocardial infarction.

& Anversa, P. (1996). Apoptotic and necrotic myocyte cell deaths are independent

Reutelingsperger CP & Heidendal, GA. (2001a). Biodistribution and dosimetry of 99mTc-BTAP-annexin-V in humans. *Eur J Nucl Med* Vol.28(No. 9): 1373-1378. Kemerink GJ, Liem IH, Hofstra L, Boersma HH, Buijs WC, Reutelingsperger CP &

Heidendal, G. A. (2001b). Patient dosimetry of intravenously administered 99mTc-

Vanderheyden, JL, Green, AM & Verbeke, K. (2003). Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for

Bitsch, N, Gijbels, M, Verjans, JW, Narula, N, Narula, J & Reutelingsperger, CP. (2010) Annexin A5 uptake in ischemic myocardium: demonstration of reversible phosphatidylserine externalization and feasibility of radionuclide imaging. *J Nucl* 


**0**

**11**

**Dosimetry for Beta-Emitter Radionuclides by**

Pedro Pérez1, Francesca Botta2, Guido Pedroli2 and Mauro Valente3

Nowadays, there are interests as well as active investigations devoted to the study and application of radiolabeled molecules able to selectively target and irradiate tumoral cells during nuclear medicine procedures. With this kind of pharmaceuticals, spatial activity distribution with extremely non-uniform characteristics may be assessed in patients. Actually, this feature constitutes precisely the main advantage in view of maximizing the discrimination between affected and healthy tissue. The mentioned situation constitutes the main motivation for the present work. In this sense, the chapter is focused on nuclear medicine dosimetry pointing out the main features about how to implement Monte Carlo (MC) approaches to this

Nowadays, from a general point of view, therapies with radiopharmaceuticals using beta-emitter radionuclides are growing significantly and very fast. Beta-emitters can be emitters of *β*<sup>−</sup> or *β*<sup>+</sup> radiation. Commonly, *β*<sup>+</sup> emitters, like 18F are used for imaging techniques, whereas *β*− are mainly used with therapeutic purposes, to deliver high dose rate

During nuclear medicine procedures, radiopharmaceutical activity distribution may be determined by means of different modalities. Nowadays it is mainly assessed using imaging techniques but otherwise it is also possible to infer it [Stabin (2008)]. This information is then incorporated in the treatment planning system in order to obtain an estimation of the dose distribution. More specifically, patient-specific dose distribution owing to alpha, beta and/or gamma emitters can be calculated starting from activity distribution by means of either direct

On the other hand, patient-specific dosimetry requires anatomical information, which shall be further considered as input for establishing mass distribution during MC computations. Patient anatomical information can be suitably extracted from typical non-invasive imaging

Many studies have been performed by means of MC applications in Nuclear Medicine up today, both in the imaging field, and regarding dosimetry calculations [F. Botta & Valente (2011), Zubal & Harrel (1992), H. Yoriyaz & dos Santos (2001), M. Ljungberg & Strand (2002)].

techniques, like computed tomography (CT) or magnetic resonance imaging (MRI).

on tumors. Therefore, *β*− emitters are usually those of more interest for dosimetry.

**1. Introductory framework**

**1. Introduction** 

MC simulation or analytical methods.

aim.

**Means of Monte Carlo Simulations**

<sup>2</sup>*Medical Physics Department, European Institute of Oncology*

<sup>1</sup>*Agencia Nacional de Promoción Científica y Tecnológica*

<sup>3</sup>*CONICET, Universidad Nacional de Córdoba*

*Universidad Nacional de Córdoba*

1,3*Argentina* <sup>2</sup>*Italy*

